Trial · NCT06853171
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with Adverse Events (AEs) | Up to Day 43 | |
| Primary | Number of participants with Serioues AEs (SAEs) | Up to Day 43 | |
| Primary | Number of participants with AEs of Special Interest (AESIs) | Up to Day 43 | |
| Secondary | Maximum observed plasma concentration (Cmax) | Up to Day 15 | |
| Secondary | Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) | Up to Day 15 | |
| Secondary | Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) | Up to Day 15 | |
| Secondary | Time of maximum observed plasma concentration (Tmax) | Up to Day 15 | |
| Secondary | Concentration at the end of a dosing interval (Ctau) | Up to Day 15 | |
| Secondary | Cmax accumulation index (AI_Cmax) | Up to Day 15 | Ratio of maximum observed plasma concentration at steady-state on Day 5 to maximum observed plasma concentration after first dose |
| Secondary | AUC accumulation index (AI_AUC) | Up to Day 15 | Ratio of area under the concentration-time curve in 1 dosing interval at steady-state on Day 5 to area under the concentration-time curve in 1 dosing interval after first dose |
| Secondary | Ctau accumulation index (AI_Ctau) | Up to Day 15 | Ratio of concentration at the end of the dosing interval at steady-state on Day 5 to maximum observed plasma concentration after first dose |
| Secondary | Average concentration within a dosing interval at steady-state (Css-avg) | Up to Day 15 | |
| Secondary | Apparent total body clearance (CLT/F) | Up to Day 15 | |
| Secondary | Effective elimination half-life during dosing interval (T-HALF(eff)) | Up to Day 15 | |
| Secondary | T-HALFeff based on AUC observed (T-HALFeff_AUC) | Up to Day 15 | Effective elimination half-life based on degree of area under the plasma concentration-time curve accumulation observed |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06853171/registered